Skip to Content
Merck
All Photos(1)

Documents

EHU026631

Sigma-Aldrich

MISSION® esiRNA

targeting human KIF3B

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

AAATCCTGGAGCAGAAACGACAGGAAATTGCAGAGCAGAAACGTCGAGAAAGAGAAATCCAGCAACAGATGGAAAGTCGAGATGAGGAGACCTTGGAACTTAAAGAGACATACAGCTCATTGCAGCAAGAGGTGGACATCAAGACCAAAAAACTCAAAAAGCTCTTCTCCAAGCTTCAGGCAGTGAAGGCTGAGATCCATGACCTCCAAGAAGAACACATCAAGGAGCGCCAAGAGCTAGAGCAGACTCAGAATGAGCTCACCAGGGAGCTGAAACTCAAGCATCTTATTATAGAAAACTTTATCCCTCTGGAAGAAAAAAGTAAAATTATGAATAGAGCCTTCTTTGATGAAGAGGAAGATCATTGGAAACTACATCCTATAACCAGACTGGAGAACCAGCAGATGATGAAGCGGCCAGTCTCAGCCGTGGGATATAAGAGACCATTGAGCCAGCACGCAAGAATGTCCATGATGATTCGTCCAGA

Ensembl | human accession no.

ENSG00000101350

NCBI accession no.

NM_004798

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... KIF3B(9371) , KIF3B(9371)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Fu-Zhou Yao et al.
The Kaohsiung journal of medical sciences, 36(7), 515-522 (2020-04-03)
Gastric cancer (GC) is the fourth most common malignancy worldwide, with 80% mortality rate in over 70% countries. Recently, targeted therapy for GC has great clinical prospects, and it is still badly needed to find novel molecular targets to control

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service